title: Total lymphoid irradiation for multiple sclerosis.
abstract: Although chemical immunosuppression has been shown to benefit patients with chronic progressive multiple sclerosis (MS), it appears that chemotherapy has an appreciable oncogenic potential in patients with multiple sclerosis. Accordingly, we developed a modified total lymphoid irradiation (TLI) regimen designed to reduce toxicity and applied it to a randomized double blind trial of TLI or sham irradiation in MS. Standard TLI regimens were modified to reduce dose to 1,980 rad, lowering the superior mantle margin to midway between the thyroid cartilage and angle of the mandible (to avert xerostomia) and the lower margin of the mantle field to the inferior margin of L1 (to reduce gastrointestinal toxicity by dividing abdominal radiation between mantle and inverted Y), limiting spinal cord dose to 1,000 rad by custom-made spine blocks in the mantle and upper 2 cm of inverted Y fields, and also protecting the left kidney even if part of the spleen were shielded. Clinical efficacy was documented by the less frequent functional scale deterioration of 20 TLI treated patients with chronic progressive MS compared to to 20 sham-irradiated progressive MS patients after 12 months (16% versus 55%, p less than 0.03), 18 months (28% versus 63%, p less than 0.03), and 24 months (44% versus 74%, N.S.). Therapeutic benefit during 3 years follow-up was related to the reduction in lymphocyte count 3 months post-irradiation (p less than 0.02). Toxicity was generally mild and transient, with no instance of xerostomia, pericarditis, herpes zoster, or need to terminate treatment in TLI patients. However, menopause was induced in 2 patients and staphylococcal pneumonia in one. Our data suggest that this modified TLI regimen has clinical efficacy and sufficiently low toxicity to make it suitable for investigative immunosuppressive treatment of patients with progressive MS or other non-malignant conditions.
authors.affiliation: Department of Radiation Oncology, Clara Maass Medical Center, Belleville, NJ 07109.
authors.forename: C K
authors.initials: CK
authors.lastname: Devereux
authors.forename: R
authors.initials: R
authors.lastname: Vidaver
authors.forename: M P
authors.initials: MP
authors.lastname: Hafstein
authors.forename: G
authors.initials: G
authors.lastname: Zito
authors.forename: R
authors.initials: R
authors.lastname: Troiano
authors.forename: P C
authors.initials: PC
authors.lastname: Dowling
authors.forename: S D
authors.initials: SD
authors.lastname: Cook
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D007165:Immunosuppression Therapy; D008208:Lymphatic System / Q000528:radiation effects*; D008297:Male; D009103:Multiple Sclerosis / Q000276:immunology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D011879:Radiotherapy Dosage; D011897:Random Allocation